BioSpace News Archive

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended June 30, 2021 on Wednesday, August 18, 2021, before the US markets open.

BioFluidica, a privately held biotechnology company in conjunction with the University of Kansas, today announced they have been awarded a grant from the Midwest Biomedical Accelerator Research Consortium on behalf of the National Institutes of Health’s Rapid Acceleration of Diagnostics (RADx Tech) program.

Within the rapidly growing stem cell market, stem cell manufacturing is important.

The market is estimated to grow at a CAGR of 4.8% from 2020 to 2027.

The OTCQB is the venture tier of OTC Markets on which 11,000 U.S. and global securities trade.

Surge in number of patients affected from neurological disorders drives the growth of the global deep brain stimulation devices market.

The global E-Health Market was pegged at $74.47 billion in 2019 and is expected to hit $230.64 billion by 2027, registering a CAGR of 14.5% from 2020 to 2027.

Rise in prevalence of hydrocephalus, growth in adoption of advanced programmable valves, and surge in incidences of neurological disorder drive the growth of the global hydrocephalus shunts market.

Rise in technological advancements and increasing use of medical simulation techniques various surgeries is anticipated to drive the market.

bioAffinity Technologies, a privately held company focused on early diagnostics and cancer therapeutics, announced publication in the peer-reviewed Journal of Visualized Experiments (JoVE).